Media Release, April 23, 2021

BB Biotech AG publishes its interim report

BB Biotech AG (ISIN CH0038389992) today published its interim report as at March 31, 2021, which covers the results of its business activities for the first three months of 2021.

Based on the consolidated accounts of BB Biotech AG, net profit for the period ended March 31, 2021 amounted to CHF 221 mn (loss of CHF 758 mn in the same period 2020). For an investment company, the results reflect the share price development of the companies held in the portfolio.

The interim report as at March 31, 2021 is available under report.bbbiotech.ch/Q121 or www.bbbiotech.com.

For further information:
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland
Tanja Chicherio, Tel. +41 44 267 67 07, [email protected]

www.bbbiotech.com

Company profile
BB Biotech AG is an investment company domiciled in Schaffhausen/Switzerland and listed on the stock exchanges in Switzerland, Germany and Italy. Since 1993, the company has invested in innovative drug development companies that are mainly located in the US and Western Europe.
BB Biotech AG is one of the leading investors in this sector. BB Biotech AG builds on the long-standing experience of its distinguished Board of Directors and on the fundamental analysis of the experienced Investment Management Team of Bellevue Asset Management AG when making its investment decisions.